[PHARMEDI VIETNAM 2025] Decoding Vietnam’s Golden Decade in Healthcare: Vietnam Emerges as ASEAN’s New Hotspot

Previous exhibition data

📊 Exhibition Scale: More than 600 companies from 25 countries and regions are participating in the exhibition. including global Fortune 500 companies such as Siemens Healthineers of Germany, Samsung Bioepis of South Korea, and Mindray of China, with an exhibition area exceeding 12,000 square meters.

📊 Audience Quality: Nearly 10,000 purchasing decision-makers attended, The event brings together hospital directors from Vietnam’s Top 100 hospitals, procurement directors from multinational pharmaceutical companies, and representatives from Southeast Asian distributors, with professional attendees accounting for 85% of the total.

📊 Outstanding Results: During the exhibition, 1,352 cooperation agreements were signed, and 95% of exhibitors expressed satisfaction with their participation and plan to attend the next edition.

Market Overview and Analysis

As a core ASEAN nation with a population exceeding 100 million, Vietnam’s healthcare market is experiencing explosive growth. In 2024, the medical equipment market reached US$2 billion, with an annual growth rate of 7–9%, and is projected to surpass US$2.5 billion by 2025. Demand is surging for high-end imaging equipment, laboratory instruments, and digital healthcare solutions. The pharmaceutical sector is even more robust, with the market size expected to hit US$16.1 billion by 2026, driven by a compound annual growth rate (CAGR) of 10.6%, significantly outpacing the Southeast Asian average.

② The Vietnamese government has launched the development of a 338-hectare pharmaceutical industrial park in Ho Chi Minh City, aiming to attract multinational pharmaceutical companies to localize production and accelerate the integration of the industry chain.

➤ Medical Device Sector: 90% of the market relies on imports, with international giants—Medtronic, Siemens Healthineers, and Philips—dominating the high-end segment. Among Chinese companies, those specializing in mid- to low‑end devices enjoy a clear cost‑performance advantage.

➤ Pharmaceutical sector: Domestic pharmaceutical companies meet 53% of basic drug needs, but high-end generic and innovative drugs remain heavily reliant on imports, with Chinese and Indian raw materials accounting for over 85% of the supply.

➤ Emerging sectors: Smart healthcare (AI diagnostics, remote surgery), medical tourism, and high-end insurance are experiencing robust growth, attracting global innovators to establish a presence.

√ Infrastructure Upgrades: The government plans to invest US$2.5 billion in upgrading healthcare infrastructure, prioritizing the procurement of imported equipment. Chinese medical device companies can focus on expanding their presence in diagnostic imaging systems such as CT and MRI.

√ Tariff benefits: Under the RCEP framework, import tariffs on medical devices have been reduced to 0%–5%; combined with the EVFTA agreement, Chinese companies can leverage Vietnam to access the EU market.

√ Domestic Substitution: The Vietnamese government is boosting the localization rate of medical devices, creating a window of opportunity for domestic companies to upgrade their technologies, particularly in the areas of low-cost consumables and basic equipment.

Booth reservations are now open.